Clinical Trial

Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy

Study acronym: NEO-TAN
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
evaluate the predictive value of circulating neutrophil DNA methylation profiles, identified from the ALCINA 2 cohort, on pre-treatment blood samples (T0), for the histological response to neoadjuvant chemo-immunotherapy in patients with resectable non-small cell lung cancer (NSCLC)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-07; most recent amendment 2025-07-07.
Trial Details
NCT Number NCT06974097
Lead Sponsor University Hospital, Montpellier
Conditions Non-Small Cell Lung Cancer
Enrollment 72 participants
Start Date 2025-07-01
Primary Completion 2028-07-28 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-08